Is Nicotinamide riboside (NR) worth it?
NR is good at one thing: raising NAD-related blood markers. That is not the same as proving more daily energy, better exercise capacity, or slower aging in humans. At branded-NAD prices, it is a biomarker bet, not a practical energy buy.
The call
Nicotinamide riboside is a vitamin B3-related NAD precursor, and NIH ODS describes niacin derivatives as feeding NAD chemistry involved in cellular energy metabolism. In a small randomized crossover trial in healthy middle-aged and older adults, NR raised NAD-related blood metabolites and was tolerated, but exercise capacity, glucose and insulin measures, body composition, and daily energy outcomes were not improved. In obese insulin-resistant men, a higher-dose randomized trial found no improvement in insulin sensitivity, resting energy expenditure, lipid oxidation, or body composition. The real evidence supports NAD-biomarker movement, not a dependable consumer energy or anti-aging outcome.
Safety
Short-term human trials generally report tolerability at studied doses, but long-term safety and outcome data are limited. Avoid during pregnancy, breastfeeding, and childhood unless medically supervised. Use clinician review with liver disease, kidney disease, active cancer, cancer therapy, complex metabolic disease, or heavy medication use because NAD-pathway manipulation has unresolved clinical implications. Possible side effects include nausea, flushing, cramps, headache, rash, bruising, drowsiness, or gastrointestinal upset; stop for allergic symptoms, unusual bleeding, persistent palpitations, severe GI symptoms, or new neurologic or mood changes.
Dose that matters: No proven energy dose. Human trials commonly use 500-1000 mg/day of nicotinamide riboside chloride; one metabolic trial used 2000 mg/day, but that dose did not improve insulin sensitivity or energy expenditure in obese insulin-resistant men.
Sources
Tier 2 · evidence synthesis · Reviewed by the Stack-kit desk